Yigit Safak, Eksi Busra Ulker, Satman Ilhan, Dayican Damla Korkmaz, Calikoglu Fulya, Sahin Humeyra Rekali, Perone Francesco, Akinci Buket
Department of Physiotherapy and Rehabilitation, Graduate Education Institute, Biruni University, Istanbul, Turkey.
Department Physiotherapy Program, Vocational School Therapy and Rehabilitation, Istanbul Galata University, Istanbul, Turkey.
Lipids Health Dis. 2025 Sep 23;24(1):285. doi: 10.1186/s12944-025-02701-8.
Diabetic dyslipidemia, a common comorbidity in people with type 2 diabetes, has been reported to be associated with adverse metabolic outcomes. Skeletal muscle is a key organ impacted by metabolic disorders; however, the specific effects of diabetic dyslipidemia on skeletal muscle mass, strength, and performance remain unclear. The aim of this study was to assess the skeletal muscle alterations of people with type 2 diabetes with and without dyslipidemia.
This retrospective study included 144 participants (mean age 51.3 ± 7.1 years; 103 female, 41 male) aged 40–65 years. Body composition was assessed using bioelectrical impedance analysis (BIA), muscle strength via dynamometer, and functional capacity with the 6-minute walk test (6MWT). To minimize the confounding effect of longer diabetes duration in the diabetic dyslipidemia group, propensity score matching (PSM) was performed using a 1:1 nearest-neighbor method. All analyses were performed on matched groups. ROC analysis was conducted for variables showing significant differences.
After PSM, people with diabetic dyslipidemia showed significantly lower skeletal muscle mass and skeletal muscle index (SMI), higher body fat percentage, and reduced 6MWD compared to those with diabetes alone ( < 0.05). In women with diabetic dyslipidemia, handgrip strength was significantly lower. ROC analysis revealed moderate predictive value for skeletal muscle mass (AUC = 0.682), SMI (AUC = 0.654), and 6MWD (AUC = 0.628).
This study demonstrated that people with diabetic dyslipidemia had lower skeletal muscle mass, SMI, and decreased physical performance compared to people with diabetes alone, even after matching for diabetes duration. These findings demonstrate early sarcopenic and dynapenic changes and highlight the need to consider skeletal muscle health and lipid abnormalities together in diabetes management.
[Image: see text]
糖尿病血脂异常是2型糖尿病患者常见的合并症,据报道与不良代谢结局相关。骨骼肌是受代谢紊乱影响的关键器官;然而,糖尿病血脂异常对骨骼肌质量、力量和功能的具体影响仍不清楚。本研究的目的是评估伴有和不伴有血脂异常的2型糖尿病患者的骨骼肌改变。
这项回顾性研究纳入了144名年龄在40 - 65岁的参与者(平均年龄51.3±7.1岁;女性103名,男性41名)。使用生物电阻抗分析(BIA)评估身体成分,通过测力计评估肌肉力量,采用6分钟步行试验(6MWT)评估功能能力。为了最小化糖尿病血脂异常组中糖尿病病程较长带来的混杂效应,采用1:1最近邻法进行倾向评分匹配(PSM)。所有分析均在匹配组上进行。对显示出显著差异的变量进行ROC分析。
PSM后,与单纯糖尿病患者相比,糖尿病血脂异常患者的骨骼肌质量和骨骼肌指数(SMI)显著降低,体脂百分比更高,6分钟步行距离(6MWD)缩短(<0.05)。在患有糖尿病血脂异常的女性中,握力显著降低。ROC分析显示骨骼肌质量(AUC = 0.682)、SMI(AUC = 0.654)和6MWD(AUC = 0.628)具有中等预测价值。
本研究表明,即使在匹配糖尿病病程后,糖尿病血脂异常患者的骨骼肌质量、SMI较单纯糖尿病患者更低,身体功能也有所下降。这些发现表明存在早期肌肉减少症和肌无力的变化,并强调在糖尿病管理中需要同时考虑骨骼肌健康和脂质异常。
[图像:见正文]